Updated Guidelines for Metastatic Hormone-sensitive Prostate Cancer: Abiraterone Acetate Combined with Castration Is Another Standard

Addition of docetaxel to androgen deprivation therapy (ADT) was recommended for patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), who are fit enough to receive docetaxel. Two recently published trials showed that the addition of abiraterone acetate plus prednisone t...

Full description

Saved in:
Bibliographic Details
Published in:European urology 2018-03, Vol.73 (3), p.316-321
Main Authors: Mottet, Nicolas, De Santis, Maria, Briers, Erik, Bourke, Liam, Gillessen, Silke, Grummet, Jeremy P., Lam, Thomas B., van der Poel, Henk G., Rouvière, Olivier, van den Bergh, Roderick C.N., Cornford, Philip
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Addition of docetaxel to androgen deprivation therapy (ADT) was recommended for patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), who are fit enough to receive docetaxel. Two recently published trials showed that the addition of abiraterone acetate plus prednisone to ADT has a clear survival benefit and acceptable overall tolerance, and should be considered as another standard of care for newly diagnosed mHSPC.
ISSN:0302-2838
1873-7560
DOI:10.1016/j.eururo.2017.09.029